Printer Friendly

BURROUGHS WELLCOME GIVES $1 MILLION TO COMMUNITY-BASED CLINICAL RESEARCH

BURROUGHS WELLCOME GIVES $1 MILLION TO COMMUNITY-BASED CLINICAL RESEARCH
 RESEARCH TRIANGLE PARK, N.C., June 30 /PRNewswire/ -- Burroughs Wellcome Co., a leader in worldwide antiviral research, today announced a $1 million gift to support community-based AIDS research which will be administered by the American Foundation for AIDS Research (AmFAR).
 The company's gift was prompted by an initiative spearheaded by individuals within ACT UP/New York and is intended to expand the research capabilities of more than 20 community-based research sites located throughout the country.
 The Community-based Clinical Trials (CBCT) Network includes about 1,500 physicians who care for an estimated 155,000 HIV-infected men, women and children nationwide. Community-based trials serve as an innovative alternative to traditional academic research by permitting individuals to participate in clinical research in their community through their primary care physician.
 "Since Burroughs Wellcome is at the forefront of the fight against HIV disease and its related infections, it is significant that they have chosen to support community-based trials by assuming a leadership role in this fund-raising effort," said Peter Staley, a member of ACT UP/ New York.
 "It is our hope that these funds will enable sites within the CBCT system to conduct trials at the grassroots level which will help answer many of the questions that people with HIV are asking about therapies as well as enhance their access to promising experimental regimens," said David W. Barry, vice president of research, development and medical affairs at Burroughs Wellcome.
 AmFAR Chairman Mathilde Krim applauded the increased support for the community-based research and indicated that AmFAR was pleased to serve as administrator of the Burroughs Wellcome funds and others raised through this initiative. AmFAR started funding community-based research in 1988 and has provided more than $6 million in core support and project grants since that time.
 "We at AmFAR are delighted that Burroughs Wellcome is making additional research possible," Krim said. "Joint efforts based on the common goal to bring better treatments for HIV/AIDS to patients in their communities also are portents of hope and accelerated progress in clinical research."
 Barry said community-based trials have the advantage of offering a wide range of individuals, including women and people of color, access to clinical trials without having to travel to a major academic medical center.
 He added that Burroughs Wellcome is working with a number of community-based sites in the implementation of a Treatment IND for atovaquone (566C80), an antiparasitic drug which currently is under review by the Food and Drug Administration (FDA) for the treatment of Pneumocystis cainii pneumonia.
 CBCT Network members are also collaborating on a national Observational Database designed to study the natural history of HIV disease, to observe evolving standards of medical care, and to store data collected through large multicenter trials.
 Burroughs Wellcome Co. is a research-based pharmaceutical company headquartered in Research Triangle Park. The company has a broad research program to develop innovative therapies for a number of serious illnesses, including HIV infection. In addition to the AmFAR grant, Burroughs Wellcome has provided more than $4 million to national and community-based organizations that provide HIV-related services and programs since 1987.
 -0- 6/30/92
 /CONTACT: Kathy S. Bartlett of Burroughs Wellcome, 919-248-4302, or David Kirby of AmFAR, 212-682-7440, ext. 114/ CO: Burroughs Wellcome Co. ST: North Carolina IN: MTC SU:


SH-TQ -- NY076 -- 5285 06/30/92 15:34 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1992
Words:559
Previous Article:C & C BEAUTY SALES ANNOUNCES POSTPONEMENT OF PUBLIC OFFERING
Next Article:POWELL'S BOOKS: FIRST U.S. COMMERCIAL EXPORTS TO VIETNAM DEPART FROM PORT OF PORTLAND; $50,000 ORDER INCLUDES COLLEGE TEXTBOOKS
Topics:


Related Articles
BURROUGHS WELLCOME COMPANY AWARDED 1991 CORPORATE LEADERSHIP AWARD FROM THE NATIONAL HEMOPHILIA FOUNDATION FOR COMMITMENT TO FIGHTS AIDS
BURROUGHS WELLCOME MAKES NEW PCP DRUG WIDELY AVAILABLE
BURROUGHS WELLCOME: FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF MARKETING OF ZOVIRAX FOR CHICKENPOX
BURROUGHS WELLCOME VOLUNTARILY REDUCES PRESCRIPTION DRUG PRICES TO FEDERALLY FUNDED PUBLIC HEALTH CLINICS AND GOVERNMENT AGENCIES USING FSS
BURROUGHS WELLCOME, DUKE TEAM UP IN CANCER RESEARCH
BURROUGHS WELLCOME CO. SUPPORTS HURRICANE RELIEF EFFORT
BURROUGHS WELLCOME PURCHASES GENETICS INSTITUTE STAKE IN WELGEN BIOTECH MANUFACTURING FACILITY
MISS AMERICA VISITS BURROUGHS WELLCOME CO.
BURROUGHS WELLCOME COMMENTS ON PRYOR STATEMENT
BURROUGHS WELLCOME SUPPORTS PHARMACIES IMPACTED BY EARTHQUAKE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters